Skip to main content

Novo-Nordisk A/S Value Stock - Dividend - Research Selection

Novo-nordisk a-s

ISIN: DK0060534915 , WKN: A1XA8R

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Novo Nordisk is a global healthcare company and a world leader in diabetes care. The Company has one of the broadest diabetes product portfolios in the industry, including new generation insulin, a full portfolio of modern insulin as well as a human once-daily GLP-1 analog. In addition, Novo Nordisk also has a leading position within haemophilia care and growth hormone therapy, and Novo Nordisk’s first product to treat obesity, Saxenda®, was launched in the United States in April 2015 and has now been launched in an additional 14 countries. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and the society. Headquartered in Denmark, Novo Nordisk employs approximately 42,500 employees in 75 countries and markets its products in more than 180 countries.

 

Segment information

Novo Nordisk is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments: (i) diabetes and obesity care and (ii) biopharmaceuticals. The diabetes and obesity care segment covers insulin, GLP-1, other protein-related products (such as glucagon, protein-related delivery systems and needles) and oral anti-diabetic drugs. The biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy and hormone replacement therapy.

 

Seasonality

Sales of individual products in individual markets may be subject to fluctuations from quarter to quarter. However, the Company’s consolidated operating results have not been subject to significant seasonality.

 

Raw materials

The impact on the overall profitability of Novo Nordisk from variations in raw material prices is unlikely to be significant. There is no raw material supply shortage that is expected to significantly impact the Company’s ability to supply any significant market. The Company’s production is largely based on common and readily available raw materials with relatively low price volatility. Certain specific raw materials are, however, less available. For these raw materials, it is the policy of Novo Nordisk to develop close and long-term relationships with key suppliers as well as to secure at least dual sourcing whenever possible and when relevant operate with a predefined minimum safety level of raw material inventories.

 

Market and competition

Novo Nordisk’s insulin and other pharmaceutical products are marketed and distributed through subsidiaries, distributors and independent agents with responsibility for specific geographical areas. In 2016, Novo Nordisk reported based on a regional structure comprising the USA, Europe, International Operations, China and Pacific. However, a new regional structure was announced in September 2016. The new regional structure for reporting will be implemented in January 2017. The new regional structure is comprised of two main commercial units: North America (the United States and Canada) and International Operations. International Operations will cover all countries except for North America and will be organised in the following five regions: Europe; Latin America; AAMEO (Africa, Asia, Middle East & Oceania); Japan & Korea; and Region China. For 2016, the most important markets are the United States, China, Japan and the major European countries. In addition there is an increasing contribution to Novo Nordisk’s total sales from the following markets: Brazil, India, Turkey, Algeria, Saudi Arabia, Iran, Argentina and Russia.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


abrdn World Healthcare Fund Q1 2025 Commentary

2025-06-03
The equity portion of the Fund rose (gross of fees) but underperformed its benchmark over the quarter.

Why Novo Nordisk (NVO) is a Top Dividend Stock for Your Portfolio

2025-06-02
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes? Let's find out.

Weight Loss Drug ETF (THNR) Hits New 52-Week High

2025-06-02
THNR hits a 52-week high, fueled by gains in Eli Lilly and Novo Nordisk -- could the rally still have legs?

Hims to cut 4% of workforce amid ban on weight-loss drug copies

2025-05-30
NEW YORK (Reuters) -Telehealth platform Hims & Hers said on Friday it will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S. ban on manufacturing mass copies of the weight-loss drug Wegovy. A U.S. Food and Drug Administration ban on compounded copies of Wegovy, made by Novo Nordisk, took effect on May 22. The company said it is seeking new opportunities for growth, including an agreement with Novo to help patients access Wegovy.

2 Top Stocks to Buy With Less Than $100

2025-05-30
Novo Nordisk should perform well thanks to new leadership and a strong underlying business. Exelixis' main oncology franchise is safe for now even as it seeks to develop newer products. When investing on a budget, buying fractional shares of top companies is one option.

2 Beaten-Down Stocks to Buy on the Dip

2025-05-30
Novo Nordisk has strengths, including a deep pipeline, that should help it overcome recent obstacles. Cava Group's results are excellent, and in the long run the restaurant chain still has strong potential. Novo Nordisk (NYSE: NVO) and Cava Group (NYSE: CAVA) are excellent choices.

How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race

2025-05-30
Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant consistently led the pack in new prescriptions, becoming virtually synonymous with a booming weight loss drug market that could hit $139 billion by 2030.

Was Jim Cramer Right About Eli Lilly and Company (LLY)?

2025-05-29
We recently published a list of Did Jim Cramer Nail or Miss These 11 Stock Predictions? In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that Jim Cramer discusses. In that episode, a caller asked about Eli Lilly and Company (NYSE:LLY), particularly in […]

Meet the New Group of Weight-Loss Drugs. The Industry Is Betting Big on Amylin.

2025-05-29
Amylin seems to be easier on the gut than GLP-1s like Ozempic, though it may produce less weight loss.

Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly

2025-05-29
Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.